TransMedics Group, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Waleed H. Hassanein
- Full Time Employees
- 728
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 200 Minuteman Road Andover MA United States of America 01810
- IPO Date
- May 2, 2019
- CIK
- 0001756262
- Website
- transmedics.com
- Similar Companies
- Business
- TransMedics Group, Inc. develops and commercializes medical technologies that transform organ transplant therapy for patients with end-stage heart, lung and liver failure; the company offers the Organ Care System (OCS), a portable extracorporeal warm perfusion, optimization and monitoring platform that replicates near-physiologic conditions for donor organs outside the body, with specific systems for hearts, lungs and livers; it also provides the National OCS Program (NOP), an end-to-end outsourced solution encompassing organ procurement, OCS perfusion management, transplant logistics and aviation transportation services, supported by trained surgeons, clinical specialists and coordinators. TransMedics operates primarily in the United States, with international reach, and targets transplant centers serving patients with end-stage organ failure. Founded in 1998 and headquartered in Andover, Massachusetts, the company continues to expand its capabilities through recent aircraft fleet acquisitions, including a fixed-wing plane purchased in January 2025 for $14.1 million from RCS Leasing, LLC, bringing its total to 20 aircraft as part of the NOP to enhance donor organ transportation.
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments
TransMedics: Why I'm Still Bullish After The Collapse
3 Growth Stocks Worth $5,000 of Your Money -- Even in This Market
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics: Despite Earnings Miss, Growth Story Remains Intact
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
TransMedics: Cheaper, But Still Priced For Perfection
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say
TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates
TransMedics Reports First Quarter 2026 Financial Results
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
TransMedics: Revolutionizing The Organ Transplant Market While Trading At A Discount
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
TransMedics Group (NASDAQ:TMDX) Shares Up 8.5% – Here’s What Happened